Cargando…

IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma

PURPOSE: Human interleukin-21 (IL-21) is a class I cytokine previously reported in clinical studies on immune responsive cancers. Here we report the effects of systemic IL-21 therapy on the immune system in two phase 1 trials with this novel cytokine. EXPERIMENTAL DESIGN: Recombinant IL-21 was admin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frederiksen, Klaus Stensgaard, Lundsgaard, Dorthe, Freeman, Jeremy A., Hughes, Steven D., Holm, Thomas L., Skrumsager, Birte K., Petri, Andreas, Hansen, Lasse T., McArthur, Grant A., Davis, Ian D., Skak, Kresten
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2008
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2491425/ https://www.ncbi.nlm.nih.gov/pubmed/18286285 http://dx.doi.org/10.1007/s00262-008-0479-4

Ejemplares similares

IL-21 Modulates Activation of NKT Cells in Patients with Stage IV Malignant Melanoma
por: Coquet, Jonathan M, et al.
Publicado: (2013)

Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease
por: Holm, Thomas Lindebo, et al.
Publicado: (2018)

Melanoma immunoediting by NK cells
por: Balsamo, Mirna, et al.
Publicado: (2012)

How melanoma cells inactivate NK cells
por: Pietra, Gabriella, et al.
Publicado: (2012)

Melanoma progression is associated with NK cell exhaustion
por: Pires da Silva, Ines, et al.
Publicado: (2014)

Targeting NK Cells to Enhance Melanoma Response to Immunotherapies
por: Lee, Hansol, et al.
Publicado: (2021)

Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells
por: Ojo, Evelyn O., et al.
Publicado: (2019)

Memory-like Differentiation Enhances NK Cell Responses to Melanoma
por: Marin, Nancy D., et al.
Publicado: (2021)

Ingenol Disoxate: A Novel 4-Isoxazolecarboxylate Ester of Ingenol with Improved Properties for Treatment of Actinic Keratosis and Other Non-Melanoma Skin Cancers
por: Bertelsen, Malene, et al.
Publicado: (2016)

Adoptive NK Cell Therapy: A Promising Treatment Prospect for Metastatic Melanoma
por: van Vliet, Amanda A., et al.
Publicado: (2021)

Susceptibility of Human Melanoma Cells to Autologous Natural Killer (NK) Cell Killing: HLA-Related Effector Mechanisms and Role of Unlicensed NK Cells
por: Carrega, Paolo, et al.
Publicado: (2009)

Allostimulation of patients' lymphocytes generates both T and NK-like cells cytotoxic for autologous melanoma.
por: Balsari, A., et al.
Publicado: (1985)

Role of NK Cell Subsets in Organ-Specific Murine Melanoma Metastasis
por: Ballas, Zuhair K., et al.
Publicado: (2013)

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
por: Tallerico, Rossana, et al.
Publicado: (2015)

Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer
por: Kelleher, Fergal C., et al.
Publicado: (2012)

Identification of Human NK17/NK1 Cells
por: Pandya, Abhilash D., et al.
Publicado: (2011)

Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34(+) progenitor cell-derived NK cells
por: van Vliet, Amanda A., et al.
Publicado: (2023)

NK Cell Plasticity in Cancer
por: Liu, Sizhe, et al.
Publicado: (2019)

Decision making in NK cells
por: Urlaub, D, et al.
Publicado: (2009)

Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF
por: Worm, Jesper, et al.
Publicado: (2009)

Addition of Interleukin-21 for Expansion of T-Cells for Adoptive Immunotherapy of Murine Melanoma
por: Zoon, Christine Kathryn, et al.
Publicado: (2015)

When unity makes strength: Combinatorial NK cell-based immunotherapies against melanoma
por: Messaoudene, Meriem, et al.
Publicado: (2014)

Circulating CD56(bright) NK cells inversely correlate with survival of melanoma patients
por: de Jonge, Kaat, et al.
Publicado: (2019)

Arenavirus Induced CCL5 Expression Causes NK Cell-Mediated Melanoma Regression
por: Bhat, Hilal, et al.
Publicado: (2020)

Escape from NK cell tumor surveillance by NGFR-induced lipid remodeling in melanoma
por: Lehmann, Julia, et al.
Publicado: (2023)

NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade
por: Kohlhapp, Frederick J, et al.
Publicado: (2015)

NK-cell fratricide: Dynamic crosstalk between NK and cancer cells
por: Nakamura, Kyohei, et al.
Publicado: (2013)

The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
por: Yu, Yanlin
Publicado: (2023)

S234: CLINICAL-GRADE MBIL21/4-1BBL EXPANDED NK CELLS EXHIBIT STRONGER COMPETENCE COMPARED WITH PRIMARY NK CELLS AGAINST HCMV INFECTION
por: Shang, Q.-N., et al.
Publicado: (2022)

Novel combination therapies for BRAF-mutant melanoma
por: McArthur, Grant A
Publicado: (2015)

NK Cell–Like Behavior of Vα14i NK T Cells during MCMV Infection
por: Wesley, Johnna D., et al.
Publicado: (2008)

Sub-apoptotic dosages of pro-oxidant vitamin cocktails sensitize human melanoma cells to NK cell lysis
por: Tremante, Elisa, et al.
Publicado: (2015)

JNK1 Deficient Insulin-Producing Cells Are Protected against Interleukin-1β-Induced Apoptosis Associated with Abrogated Myc Expression
por: Prause, Michala, et al.
Publicado: (2016)

Unhurried NK cells
por: Van Epps, Heather L.
Publicado: (2006)

CAM and NK Cells
por: Takeda, Kazuyoshi, et al.
Publicado: (2004)

NK Cells and Psoriasis
por: Dunphy, Sinéad, et al.
Publicado: (2011)

NK Cell Exhaustion
por: Bi, Jiacheng, et al.
Publicado: (2017)

Migration of NK cells
por: Gismondi, Angela, et al.
Publicado: (2006)

NK cells and chemokines
por: Gismondi, Angela, et al.
Publicado: (2010)

NK-/T-cell lymphomas
por: Wang, Hua, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dggvv68lr5ugv5h96jgpt6lvdh